Central Railway invites application for 48 paramedical posts; here's how to apply before deadline ends on 2 Sep

-

The Central Railway has released a notification for recruitment of contract-based paramedical staff in Group C as staff nurse, pharmacist, lab and X-ray technicians.

Candidates can apply by sending email to persbrbsl@gmail.com along with scanned copies of their documents or certificates in PDF by 2 September till 6 pm.

The engagement will be on full-time basis for three months, or up to 31 December 2020, for COVID-19 ward at Divisional Railway Hospital in Bhusawal.

As per a report by Times Now, the recruitment drive is carried out to fill 26 posts of staff nurse, three pharmacists, 10 lab technicians and nine X-ray technicians.

Instead of walk-in interviews, Central Railway will be holding recorded conference calls on WhatsApp/Skype from retired staff nurses, pharmacists, lab technicians and X-ray technicians or of Railways.

The interviews on WhatsApp/Skype are scheduled between 4 to 10 September. The timings are 10 am to 5 pm.

According to a report by The Times of India, candidates applying for staff nurse posts should be between 20 and 40 years. For Pharmacists, lower age is 20 and upper age is 35.

The lower age limit for lab technician and X-ray technician posts are 18 years and 19 years, respectively. The upper age limit for both the posts is 33 years.

The age will be reckoned as on 26 September 2020.

Age relaxation will be given to the SC/ST/OBC/PwBD category candidates as per the extent rule.
The notification by Central Railway stated that original documents of the shortlisted candidates will be verified at the time of joining.

Those selected for staff nurse posts will be getting a monthly fee of Rs 44,900 per month. Lab technicians will be getting remuneration of Rs 35,400 per month.

Pharmacists and X-ray technicians will be receiving a pay of Rs 29,200 per month.

For other details on Central Railway recruitment, click here.



from Firstpost India Latest News https://ift.tt/2YHhTJ6
FP Trending

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

Aditya L1 Mission: Spacecraft is nearing its final phase, says ISRO chief

-
Aditya L1 spacecraft is nearing its final phase, and manoeuvres to enter the L1 point are expected to be completed by January 7, 2024, according to ISRO Chairman S Somanath. “Aditya is on the way. I think it has reached almost its final phase,” the ISRO chief told PTI on the sidelines of an event organised at VSSC to commemorate the 60th year of the First Sounding Rocket Launch. Aditya L1, India’s first space-based mission to study the Sun, was successfully launched on September 2 from the Satish Dhawan Space Centre (SDSC) in Sriharikota. The spacecraft, after travelling about 1.5 million km from Earth over 125 days, is expected to be placed in a Halo orbit around the Lagrangian point L1, considered closest to the Sun. He said that the last preparations for the spacecraft’s entry into the L1 point are currently underway incrementally.”Possibly by January 7th, the final manoeuvres will be done for entering into the L1 point,” Somanath added. Among other tasks, it will capture and tr
Read more